Alexion Pharmaceuticals Inc. Release: New Data Evaluating Asfotase Alfa in Infants and Young Children with Hypophosphatasia (HPP) Presented at Paediatric Endocrinology Meeting
Published: Sep 23, 2013
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that researchers have presented data from an ongoing multinational Phase 2 study of asfotase alfa in infants and young children with hypophosphatasia (HPP), an inherited, ultra-rare metabolic disorder that in this patient population leads to progressive damage to multiple vital organs, destruction and deformity of bones, and death.
Help employers find you! Check out all the jobs and post your resume.